$330M Boost for Ollin Biosciences as It Preps Phase 3 Trials for Retinal Therapy
Event summary
- Ollin Biosciences raises $330M in oversubscribed Series B round led by TCGX and ARCH Venture Partners.
- Proceeds will fund global Phase 3 trials for IBI324 (OLN324), a VEGF/Ang2 bispecific antibody targeting DME and wet AMD.
- Phase 3 trials expected to begin in the second half of 2026, including sites in China and South Korea through Innovent partnership.
- IBI324 showed faster retinal drying and greater vision gains compared to Vabysmo® in head-to-head JADE clinical trial.
The big picture
Ollin Biosciences' significant Series B funding underscores investor confidence in the potential of IBI324 to challenge existing treatments for retinal vascular diseases. The $15 billion retina market is highly competitive, with established therapies like Vabysmo® and Eylea HD®. Ollin's ability to differentiate its product through superior clinical outcomes will be critical in capturing market share.
What we're watching
- Clinical Trial Execution
- The pace at which Ollin Biosciences can initiate and complete global Phase 3 trials for IBI324 will determine its competitive positioning in the $15 billion retina market.
- Regulatory Approval Pathway
- Whether the constructive feedback from FDA and EMA translates into a streamlined approval process for IBI324, potentially accelerating its market entry.
- Commercialization Strategy
- How Ollin Biosciences plans to leverage its strong investor syndicate to support the commercial launch of IBI324, particularly in key markets like China and South Korea.